Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 12379.17 | 1.0226 | 1.0785 | 0.5805 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 12379.17 | 0.9829 | 0.9413 | 0.5805 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 10938.145 | 0.9434 | 0.8976 | 1.1073 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 10938.145 | 0.7094 | 0.4669 | 1.1073 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 10938.145 | 0.6067 | 0.2736 | 1.1073 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 10938.145 | 0.8476 | 0.7225 | 1.1073 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 10938.145 | 0.8646 | 0.7537 | 1.1073 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 10938.145 | 0.8569 | 0.7396 | 1.1073 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 10938.145 | 0.7847 | 0.6068 | 1.1073 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 10938.145 | 0.8899 | 0.7999 | 1.1073 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 10938.145 | 0.8601 | 0.7455 | 1.1073 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 12333.17 | 1.0096 | 1.0288 | 0.6683 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 12333.17 | 1.0254 | 1.0766 | 0.6683 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 12333.17 | 1.0056 | 1.0169 | 0.6683 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 12333.17 | 0.9071 | 0.7284 | 0.6683 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 12333.17 | 0.9136 | 0.7471 | 0.6683 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 12333.17 | 0.9500 | 0.8523 | 0.6683 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 12333.17 | 0.8985 | 0.7039 | 0.6683 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 12333.17 | 0.9418 | 0.8283 | 0.6683 | |
| MDA-MB-415 | HR+ | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 12333.17 | 0.9382 | 0.8178 | 0.6683 | |
| MDA-MB-453 | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 12414.17 | 1.0134 | 1.0223 | 1.2052 | |
| MDA-MB-453 | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 12414.17 | 1.0026 | 1.0042 | 1.2052 | |
| MDA-MB-453 | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 12414.17 | 1.0426 | 1.0705 | 1.2052 | |
| MDA-MB-453 | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 12414.17 | 1.0558 | 1.0922 | 1.2052 | |
| MDA-MB-453 | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 12414.17 | 1.0167 | 1.0277 | 1.2052 |